Business Context and Reporting Period
This Form 8-K Current Report was filed by Relmada Therapeutics, Inc. (RLMD) on December 24, 2019, covering events occurring on December 19, 2019. The filing primarily addresses corporate governance changes, specifically the appointment of two new directors and a strategic shift in the company's fiscal year-end.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and administrative changes.
Material Changes
- Board Appointments: The Board appointed Eric Schmidt (Class I) and John Glasspool (Class III) as directors effective December 19, 2019.
- Committee Assignments:
- Dr. Schmidt: Chairman of the Audit Committee; member of the Corporate Governance and Nominating Committee.
- Mr. Glasspool: Chairman of the Corporate Governance and Nominating Committee; member of the Compensation Committee.
- Fiscal Year Change: The Board approved changing the fiscal year-end from June 30 to December 31, effective for the 2020 fiscal year (January 1, 2020, to December 31, 2020).
- Transition Reporting: The company plans to file a Form 10-KT for the transition period of July 1, 2019, through December 31, 2019.
Compensation and Agreements
Both new directors entered into agreements effective December 19, 2019, with the following terms:
- Annual Cash Compensation: $60,000 per year for each director, payable quarterly.
- Equity Grant: 200,000 stock options each, with a 10-year term and an exercise price equal to the share price on December 19, 2019.
- Vesting Schedule: 25% vests on the first anniversary; the remaining 75% vests in equal quarterly increments over the subsequent three years.
- Committee Fees:
- Dr. Schmidt: $20,000 (Audit Committee Chair) + $7,000 (Governance Committee Member).
- Mr. Glasspool: $14,500 (Governance Committee Chair) + $7,000 (Compensation Committee Member).
- Indemnification: Both directors entered into indemnity agreements with the company.
Outlook and Risks
The filing does not provide specific financial guidance, risk factors, or contingencies beyond the standard operational changes. The appointment of directors with significant biotechnology and financial experience (Dr. Schmidt with over 25 years in biotech/finance and Mr. Glasspool with over 25 years in biotech) suggests a strategic focus on strengthening corporate governance and industry expertise.
Investor Verification Checklist
- Verify the impact of the fiscal year change on future reporting schedules and the upcoming Form 10-KT filing.
- Review the full text of the Director Agreements (Exhibits 10.1 and 10.3) and Indemnity Agreements (Exhibits 10.2 and 10.4) for specific termination clauses or additional terms.
- Confirm the exercise price of the 400,000 total options granted based on the closing stock price on December 19, 2019.
- Monitor the transition period financial results (July 1, 2019 – December 31, 2019) once the Form 10-KT is filed.